PURPOSE: This is the first report on the development and initial validation of the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire, a 45-item self-report instrument designed to measure health-related quality of life (HRQL) in patients with hepatobiliary cancers. The FACT-Hep consists of the 27-item FACT-G, which assesses generic HRQL concerns, and the newly validated 18-item Hepatobiliary Subscale (HS), which assesses disease-specific issues. PATIENTS AND METHODS: The development of the HS followed a four-phase process of item generation, item reduction, scale construction, and reliability/validity testing. Two independent samples were studied: item generation (sample 1; n = 30) and reliability/validity testing (sample 2; n = 51). RESULTS: In sample 2, all subscales and aggregated scores showed high internal consistency at initial assessment (Cronbach's alpha range, 0.72 to 0.94) and retesting (Cronbach's alpha range, 0.81 to 0.94). Measurement stability over a 3- to 7-day period was also high for all aggregated scales (test-retest correlation range, 0.84 to 0.91; intraclass correlation coefficient range, 0.82 to 0.90). Convergent and divergent validity were demonstrated by examining relationships between FACT subscales and mood, social support, and social desirability. Finally, when performance status and treatment status were used to divide sample 2, the HS differentiated groups to a degree comparable to the Physical and Functional Well-Being subscales of the FACT-G, thereby contributing favorably to a 32-item Trial Outcome Index. In addition to the 18 validated, scored items in the HS, seven treatment-related items may be appended, if clinically indicated, as a separate subscale. CONCLUSION: The 45-item FACT-Hep can be used independently as a brief measure of disease-related symptoms and functioning. Alone or paired with the FACT-G, the HS has promise for use in assessing the disease-specific HRQL of patients with hepatobiliary cancers.
PURPOSE: This is the first report on the development and initial validation of the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire, a 45-item self-report instrument designed to measure health-related quality of life (HRQL) in patients with hepatobiliary cancers. The FACT-Hep consists of the 27-item FACT-G, which assesses generic HRQL concerns, and the newly validated 18-item Hepatobiliary Subscale (HS), which assesses disease-specific issues. PATIENTS AND METHODS: The development of the HS followed a four-phase process of item generation, item reduction, scale construction, and reliability/validity testing. Two independent samples were studied: item generation (sample 1; n = 30) and reliability/validity testing (sample 2; n = 51). RESULTS: In sample 2, all subscales and aggregated scores showed high internal consistency at initial assessment (Cronbach's alpha range, 0.72 to 0.94) and retesting (Cronbach's alpha range, 0.81 to 0.94). Measurement stability over a 3- to 7-day period was also high for all aggregated scales (test-retest correlation range, 0.84 to 0.91; intraclass correlation coefficient range, 0.82 to 0.90). Convergent and divergent validity were demonstrated by examining relationships between FACT subscales and mood, social support, and social desirability. Finally, when performance status and treatment status were used to divide sample 2, the HS differentiated groups to a degree comparable to the Physical and Functional Well-Being subscales of the FACT-G, thereby contributing favorably to a 32-item Trial Outcome Index. In addition to the 18 validated, scored items in the HS, seven treatment-related items may be appended, if clinically indicated, as a separate subscale. CONCLUSION: The 45-item FACT-Hep can be used independently as a brief measure of disease-related symptoms and functioning. Alone or paired with the FACT-G, the HS has promise for use in assessing the disease-specific HRQL of patients with hepatobiliary cancers.
Authors: Yael Schenker; Nathan Bahary; Rene Claxton; Julie Childers; Edward Chu; Dio Kavalieratos; Linda King; Barry Lembersky; Greer Tiver; Robert M Arnold Journal: J Palliat Med Date: 2017-08-03 Impact factor: 2.947
Authors: Aimee M Moore; T Clark Gamblin; David A Geller; Michael N Youssef; Kristin E Hoffman; Leigh Gemmell; Sonja M Likumahuwa; Dana H Bovbjerg; Anna Marsland; Jennifer L Steel Journal: Psychooncology Date: 2011-05 Impact factor: 3.894
Authors: Jennifer L Steel; Kevin H Kim; Mary Amanda Dew; Mark L Unruh; Michael H Antoni; Marion C Olek; David A Geller; Brian I Carr; Lisa H Butterfield; T Clark Gamblin Journal: J Pain Symptom Manage Date: 2010-05 Impact factor: 3.612
Authors: Jennifer L Steel; Lauren Terhorst; Kevin P Collins; David A Geller; Yoram Vodovotz; Juliana Kim; Andrew Krane; Michael Antoni; James W Marsh; Lora E Burke; Lisa H Butterfield; Frank J Penedo; Daniel J Buysse; Allan Tsung Journal: Psychosom Med Date: 2018-06 Impact factor: 4.312
Authors: Cyrill Wehling; Daniel Hornuss; Pasquale Schneider; Christoph Springfeld; Katrin Hoffmann; De-Hua Chang; Patrick Naumann; Markus Mieth; Thomas Longerich; Clemens Kratochwil; Arianeb Mehrabi; Annika Gauss; Karl Heinz Weiss; Jan Pfeiffenberger Journal: J Cancer Res Clin Oncol Date: 2019-08-19 Impact factor: 4.553
Authors: Matthias M Dollinger; Christine Lautenschlaeger; Joachim Lesske; Andrea Tannapfel; Anna-Dorothea Wagner; Konrad Schoppmeyer; Oliver Nehls; Martin-Walter Welker; Reiner Wiest; Wolfgang E Fleig Journal: BMC Cancer Date: 2010-08-24 Impact factor: 4.430
Authors: A D Wagner; P Buechner-Steudel; M Moehler; H Schmalenberg; R Behrens; J Fahlke; A Wein; S Behl; O Kuss; G Kleber; W E Fleig Journal: Br J Cancer Date: 2009-11-10 Impact factor: 7.640